## 1 Xpert MTB/RIF Ultra resistant and MTBDR*plus* susceptible rifampicin results in people with

# 2 tuberculosis: utility of FluoroType MTBDR and deep sequencing

- 3 Yonas Ghebrekristos (MSc)<sup>1,2</sup>, Aysha Ahmed (ND)<sup>2</sup>, Natalie Beylis (MBBCH)<sup>3</sup>, Sarishna Singh
- 4 (MMed)<sup>1,2</sup>, Christoffel Opperman (MMed)<sup>1,2,3</sup>, Fahd Naufal (MPH)<sup>5</sup>, Megan Folkerts (MS)<sup>4</sup>, David
- 5 Engelthaler (PhD)<sup>4</sup>, Erick Auma (MSc)<sup>1</sup>, Rouxjeane Venter (PhD)<sup>1</sup>, Ghowa Booley (MMed)<sup>3</sup>, John
- 6 Metcalfe (PhD)<sup>5</sup>, Robin Warren (PhD)<sup>1</sup>, Grant Theron (PhD)<sup> $1\dagger$ </sup>

# 7 Affiliations:

- 8 <sup>1</sup>DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, and SAMRC Centre for
- 9 Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and
- 10 Health Sciences, Stellenbosch University, Tygerberg, Cape Town, South Africa.
- <sup>11</sup> <sup>2</sup>National Health Laboratory Service, Greenpoint Tuberculosis Laboratory, Cape Town, South Africa.
- <sup>3</sup>Division of Medical Microbiology, Department of Pathology, University of Cape Town, Cape Town,
- 13 South Africa.
- <sup>4</sup>Translational Genomics Research Institute, Flagstaff, Arizona, USA.
- <sup>5</sup>University of California San Francisco, San Francisco, California, USA.
- <sup>†</sup>**Corresponding author:** Prof Grant Theron, BMRI Building, 2<sup>nd</sup> Floor, Room, Faculty of Health
- 17 Sciences, Department of Molecular and Biology and Human Genetics, Francie van Zijl Drive,
- 18 Tygerberg Campus, Tygerberg 7505, South Africa.
- 19 E-mail: gtheron@sun.ac.za
- 20 Keywords: tuberculosis, diagnosis, rifampicin susceptibility, heteroresistance

#### 21 Summary (249/250)

<u>Background:</u> Xpert MTB/RIF Ultra (Ultra)-detected rifampicin-resistant tuberculosis (TB) is often
 programmatically confirmed using MTBDR*plus*. There are limited data on discordant results,
 including re-tested using newer methods like FluoroType MTBDR (FT-MTBDR) and targeted deep
 sequencing.

26 <u>Methods:</u> MTBDR*plus* rifampicin-susceptible isolates from people with Ultra rifampicin-resistant 27 sputum were identified from a South African programmatic laboratory. FT-MTBDR and single 28 molecule-overlapping reads deep (SMOR; *rpoB*, *inhA*, *katG*) on isolate DNA were done (SMOR 29 reference standard).

30 Findings: Between 01/04/2021-30/09/2022, 8% (109/1347) of Ultra rifampicin-resistant specimens 31 were MTBDRplus-susceptible. Of 89% (97/109) isolates with a sequenceable rpoB, SMOR resolved 32 most in favour of Ultra [79% (77/97)]. Sputum with lower mycobacterial load was associated with 33 Ultra false-positive resistance [46% (11/24) of "very low" Ultras had false-resistance vs. 12% (9/73; 34 p=0.0004) in those  $\geq$ "low"], as were Ultra heteroresistance calls (all wild type probes,  $\geq$ 1 mutant 35 probe) [62% (23/37 vs. 25% (15/60) for Ultra without heteroresistance calls; p=0.0003]. Of the 91% 36 (88/97) of isolates successfully tested by FT-MTBDR, 55% (48/88) were FT-MTBDR rifampicin-37 resistant and 45% (40/88) susceptible, translating to 69% (47/68) sensitivity and 95% (19/20) 38 specificity. In the 91% (99/109) of isolates with inhA and katG sequenced, 62% (61/99) were SMOR 39 isoniazid-susceptible. 40 Interpretation: When Ultra and MTBDR*plus* rifampicin results are discordant, Ultra is more likely to 41 be correct and FT-MTBDR agrees more with Ultra than MTBDRplus, however, lower load and the

Ultra heteroresistance probe pattern were risk factors for Ultra false rifampicin-resistant results. Most
 people with Ultra-MTBDR*plus* discordant resistance results were isoniazid-susceptible. These data
 have implications for drug-resistant TB diagnosis.

45 <u>Funding:</u> This work was supported by European & Developing Countries Trial Partnerships
46 (EDCTP2; RIA2020I-3305, CAGE-TB), National Institutes of Health (D43TW010350;

47 U01AI152087; U54EB027049; R01AI136894).

## 48 Introduction

49 Xpert MTB/RIF Ultra (Ultra; Cepheid, Sunnyvale, USA) is a widely used test for diagnosing 50 tuberculosis (TB) and detecting rifampicin-resistance. Endorsed by the WHO, Ultra has been an 51 essential screening tool in high-incidence countries, such as South Africa, where it has been used 52 routinely since 2011. At the time of this study, in the South African TB Control programme, if Ultra 53 detected rifampicin-resistance, a second specimen is typically cultured. The resulting TB isolate can 54 be tested with GenoType MTBDRplus VER 2.0 (MTBDRplus, Bruker-Hain Lifescience, Nehren, 55 Germany) which confirms the rifampicin-resistance and can additionally detect isoniazid resistance. 56 However, discrepancies between results obtained directly from the patient specimen and those from 57 cultured isolates or other molecular assays can occur, complicating both reporting and clinical 58 management. This discordance, which could be due to heteroresistance, can lead to poor outcomes,<sup>1</sup> 59 patient distress and significant financial burdens due to delays and additional testing.

60 Although superseded in some settings by FluoroType MTBDR VER 2.0 (FT-MTBDR; Bruker-Hain Lifescience, Nehren, Germany),<sup>2, 3</sup> MTBDR*plus* is widely used for confirmatory drug susceptibility 61 testing (DST). Both Ultra and MTBDRplus target the rpoB rifampicin-resistant determining region 62 63 (RRDR) of Mycobacterium tuberculosis complex (MTBC). Reports from our high burden setting of 64 South Africa highlight discordance in ~ 7% of Xpert MTB/RIF (Xpert; Ultra's predecessor) resistant samples, which were MTBDR*plus* rifampicin-susceptible.<sup>4, 5</sup> Sub-optimal Xpert readouts, particularly 65 in the "very low" semi-quantification category, and probe delay have been linked to false-rifampicin-66 resistance calls.<sup>6</sup> However, this has not vet been studied in the context of Ultra. Aside from factors 67 68 like human error or cross-contamination, discordant results may also arise due to heteroresistance and 69 culture bias, as Ultra is performed directly on specimens while MTBDRplus is typically conducted on cultured isolates.7-9 70

Two additional critical gaps exist. First, although Ultra itself does not directly report rifampicin heteroresistance, probe melting temperatures have been suggested as a potential tool for inferring heteroresistance (if a specific probe has melting temperatures corresponding to both wild-type and mutant strains).<sup>10</sup> However, the diagnostic accuracy of such Ultra's heteroresistance calls on clinical specimens has not been evaluated. Second, it is unclear whether the level of discordance between Ultra and FT-MTBDR, which utilizes LiquidArray technology to detect MTBC and mutations in *rpoB*, *inh*A, and *kat*G genes, is comparable to that observed with MTBDR*plus*.<sup>2</sup>

We sought to address these knowledge gaps in individuals identified programmatically as having discordant rifampicin results (Ultra-resistant, MTBDR*plus*-susceptible). To ascertain true rifampicin susceptibility status, we employed targeted deep sequencing with single molecule-overlapping reads (SMOR) as a reference standard.<sup>7, 9</sup> Additionally, we used FT-MTBDR as a comparator. Our study

- 82 also sought to identify test parameters associated with discordance, heteroresistance, and rifampicin
- 83 mono-resistance.

## 84 Materials and methods

#### 85 <u>Study design and setting</u>

86 The study was conducted from 1 April 2021 to 30 September 2022, using patient specimens and their

- 87 corresponding isolates processed at the high-throughput National Health Laboratory Service (NHLS)
- 88 Greenpoint TB Laboratory (Cape Town, South Africa; ~60 000 TB tests per month).
- 89 <u>Routine diagnostic algorithm</u>

90 Following the diagnostic algorithm, healthcare workers collected two sputum samples an hour apart 91 from individuals with presumptive TB. Upon laboratory receipt, one specimen was arbitrarily selected for testing with Ultra and processed according to the manufacturer's instructions.<sup>11</sup> If Ultra detected 92 93 MTBC and rifampicin-resistance, the second specimen was processed for mycobacterial culture using 94 the standard NALC-NaOH (1.25% final concentration) decontamination procedure and 0.5 ml 95 inoculated into a Mycobacterium Growth Indicator Tube 960 (MGIT960; Becton Dickinson 96 Diagnostic Systems, Sparks, USA) supplemented with polymyxin B (400 units/ml), amphotericin B 97 (40  $\mu$ g/ml), nalidixic acid (160  $\mu$ g/ml), trimethoprim (40  $\mu$ g/ml) and azlocillin (40  $\mu$ g/ml) (PANTA, 98 Becton Dickinson Diagnostic Systems) and incubated for  $\leq$ 35 days. After a tube is automatically 99 flagged growth-positive, Ziehl-Neelsen (ZN) microscopy was performed to detect acid-fast bacilli 100 (AFB). If AFBs were observed, MTBDRplus was conducted on the MGIT culture according to the 101 manufacturer's protocol, using the GenoScan instrument with semi-automated reading and manual confirmation.<sup>12</sup> All MGIT isolates were stored at room temperature. 102

103 *Discordant isolate selection and definition of Ultra heteroresistance results* 

We selected MTBDR*plus* rifampicin-susceptible isolates from specimens collected concurrently with those tested by Ultra (**Figure 1**). Patients were classified as Ultra heteroresistant based on the melting temperature curve peaks for each *rpoB* probe as previously described.<sup>10</sup> Briefly, if each probe exhibited melting peaks corresponding to the wild-type temperature in addition to at least one *rpoB* mutant melting peak, the result was designated heteroresistant (**Figure 2**).

109 <u>FluoroType MTBDR</u>

DNA Extraction: 500 μl of MGIT960 growth culture was treated with 167 μl of inactivation reagent
(room temperature, 30 min) and DNA was extracted using the GXT96 X2 Extraction Kit VER1.0
(Bruker-Hain Lifescience, Nehren, Germany) with the GenoXtract fleXT instrument (Bruker-Hain
Lifescience, Nehren, Germany), as per the manufacturer's instructions.<sup>13</sup> With each extraction, saline
buffer and un-inoculated MGIT960 (supplemented with PANTA) were included as a negative control,
alongside the provided positive control.

- 116 PCR: Extracted DNA was amplified using the FluoroCycler XT (Bruker-Hain Lifescience, Nehren,
- 117 Germany) and analysed with the controls using FluoroSoftware XT-IVD (version 1.0.1.5.5.75;
- 118 Bruker-Hain Lifescience, Nehren, Germany).
- 119 <u>Single Molecule Overlapping Reads (SMOR)</u>

DNA extraction: Briefly, 100 μl of growth from the MGIT960 tube was heated at 100°C for 30 min,
 as previously described.<sup>14</sup>

122 Sequencing: Primers were used to amplify inhA, katG, and rpoB resistance determining regions as

123 described (Supplementary Material pp2).<sup>15</sup> A second PCR added adapters using a previously

124 published universal tail method. Samples were pooled and sequenced on an Illumina MiSeq (V3,

600bp paired-end chemistry). Multiple no template controls were used as quality control to ensure theintegrity of results.

Bioinformatics: The Amplicon Sequencing Analysis Pipeline (version 1.9; ASAP) was used.<sup>15, 16</sup> 127 128 which requires overlapping forward and reverse reads to agree and uses read counts to report variant 129 frequency. Resistance calls were classified by ASAP into predefined categories based on the 130 percentage of reads with a known resistance associated variant (RAV) as "microheteroresistance" 131 (0.1-<5%), "macroheteroresistant" (5-95%) or "full resistant" (>95%).<sup>8</sup> SMOR requires at least 10 132 paired reads at a locus to make a call. In this case, to call to 0.1%, 10,000 paired reads were required for reporting. When multiple RAVs were detected in a single amplicon, ASAP was used to determine 133 whether they were on the same read as previously described<sup>17</sup> and thus likely originate from a single 134 135 population (haplotype identification).

# 136 <u>Statistical analysis and definitions</u>

137 2×2 tables were used to calculate sensitivity and specificity with 95% confidence intervals (CIs, exact 138 binomial method) and using SMOR results as a reference standard for rifampicin and isoniazid. The 139 prtesti command (STATA 18, StataCorp) was used for comparisons between proportions. Results 140 were classified as successful if a test yielded a definitive resistant or susceptible result; outcomes 141 where MTBC was not detected, or results were uninterpretable were considered unsuccessful.<sup>18</sup>

142 <u>Ethics</u>

143 This study was done according to relevant guidelines and regulations, and approved by the Human 144 Research Ethics Committee, Division of Molecular and Human Genetics, Department of Biomedical 145 Sciences at Stellenbosch University, Cape Town, South Africa (S20/08/189) and the National Health 146 Laboratory Service Academic Affairs, Research and Quality Assurance, South Africa (PR2119347). 147 Permission was granted to access anonymised to-be-discarded residual samples collected as part of 148 routine diagnostic practice with waived informed consent.

149 <u>Role of funding source</u>

- 150 The funder of the study had no role in study design, data collection, data analysis, data interpretation,
- 151 or writing.

#### 152 Results

#### 153 Frequency of discordant rifampicin results

Between 01/04/2021-30/09/2022, 1623 patients with Ultra rifampicin-resistance were identified.
MTBDR*plus* was performed on 91% (1483/1623) of these samples, with 91% (1347/1483) yielding
determinate results for rifampicin susceptibility. Of these, 8% (109/1347) were MTBDR*plus*rifampicin-susceptible, and hence discordant with Ultra (Figure 1).

158 <u>Relationship between Ultra and SMOR rifampicin results</u>

159 RAV frequency: Of 92% (100/109) Ultra-MTBDRplus discordant isolates available for SMOR, 97% 160 (97/100) generated a successful result; 39% (38/97) were classified as full resistant, 19% (18/97) 161 macroheteroresistant, 21% (20/97) microheteroresistant, and the remainder 21% (20/97) had no 162 resistance-associated reads. Therefore, the positive predictive value (PPV) of Ultra rifampicin-163 resistance for true rifampicin-resistance (as defined by a SMOR reference standard) was 79% (77/97), 164 with 21% (20/97) of Ultra results correspondingly being false-positive for rifampicin-resistance. 165 Lower Ultra-detected load (higher  $C_{Tmin}$ ) was positively associated with false-positive results [median 166 (IQR)  $C_{Tmin}$  29 (28-31) vs. 19 (18-25) in true positives; p=0.0001]. Specifically, in Ultra results with a 167 "very low" semi-quantitation category, 46% (11/24) had false resistance compared to 12% (9/73 168 p=0.0004) in those with a higher semi-quantitation category [when restricted to those with Ultra 169 heteroresistant patterns these were 75% (6/8) vs. 21% (6/29); p=0.0037] (Table 1).

# 170 *Heteroresistance*

171 Thirty-nine percent (38/97) of people had SMOR-detected heteroresistance and 38% (37/97) of Ultra 172 results exhibited heteroresistant probe patterns. Among these Ultra results, 67% (25/37) had SMOR-173 detected resistance with two classified as resistant, 11 as macroheteroresistant, and 12 as 174 microheteroresistance; 12 were classified as susceptible by SMOR. Of the 60 Ultra results without 175 heteroresistant patterns, 87% (52/60) had SMOR-detected resistance with 37 classified as resistant, 176 seven as macroheteroresistant, and eight as microheteroresistant; eight were classified as susceptible 177 by SMOR. SMOR-detected heteroresistance was more common in Ultra-detected heteroresistance 178 isolates compared to those without Ultra-detected heteroresistance [62% (23/37) vs. 25% (15/60); 179 (p=0.0003)]. Ultra heteroresistance patterns therefore had 61% (23/38) sensitivity and 95% (37/39) 180 specificity for SMOR heteroresistance. Lastly, Ultra heteroresistance was more likely than Ultra non-181 heteroresistance results to be false-positive for rifampicin-resistance [PPV, 68% (25/37) vs 182 87% (52/60); p=0.021].

*Haplotyping:* Isolates from 21% (16/77) people had two or more *rpo*B mutations detected by SMOR.
Nineteen percent (3/16) had all mutant calls on the same read and the remaining 79% (13/16) had
mutations on separate reads, suggesting they were in separate strain subpopulations.

#### 186 *Isoniazid susceptibility*

187 Thirty-eight of 99 (38%) samples demonstrated isoniazid resistance-associated mutations by SMOR 188 (22 resistant, 7 macroheteroresistant, 9 microheteroresistance; 61 susceptible); 55% (21/38) had katG 189 and 45% (17/38) inhA mutations by SMOR. Sensitivity and specificity for isoniazid resistance by 190 MTBDR*plus* were 53% (20/38) and 98% (60/61), respectively (Supplementary Material Table 2). 191 Among the isolates that were false MTBDRplus isoniazid-susceptible, 67% (12/18) had 192 heteroresistance (8 microheteroresistance). Heteroresistance was less frequent in MTBDRplus 193 isoniazid true positives, with 20% (4/20) being heteroresistant (3 macroheteroresistance). Notably, of 194 the 77 isolates that were SMOR rifampicin-resistant, 56% (43/77) were isoniazid-susceptible 195 (rifampicin mno-resistant).

#### 196 *FluoroType MTBDR*

*Rifampicin:* From the usable rifampicin SMOR results, 91% (88/97) also had successful FT-MTBDR results with 55% (48/88) resistant (Ultra-concordant) and 45% (40/88) susceptible (MTBDR*plus*concordant). FT-MTBDR sensitivity and specificity for rifampicin-resistance were 69% (47/68) and 95% (19/20), respectively (**Supplementary Material Table 2**). Amongst FT-MTBDR rifampicinsusceptible isolates, 53% (21/40) were rifampicin-resistant via SMOR. Of these, 100% (21/21) had heteroresistance (19 microheteroresistant) and in all 100% (47/47) SMOR rifampicin-resistant isolates without heteroresistance were detected correctly by FT-MTBDR.

204 Isoniazid: From the 98 people with successful isoniazid FT-MTBDR and SMOR results, 72% (71/98) 205 were FT-MTBDR susceptible and 28% (27/98) FT-MTBDR resistant. FT-MTBDR sensitivity and 206 specificity for isoniazid resistance were 71% (27/38) and 100% (60/60); respectively 207 (Supplementary Material Table 2). Among FT-MTBDR isoniazid-susceptible isolates, 15% (11/71) 208 were isoniazid-resistant by SMOR. All of these, 100% (11/11) had heteroresistance (8 209 microheteroresistant) and 100% (22/22) SMOR isoniazid-resistant without heteroresistance were 210 detected correctly by FT-MTBDR. Among people with SMOR heteroresistance, FT-MTBDR 211 correctly detected resistance in 31% (5/16).

*Compared to MTBDRplus for isoniazid resistance:* 99 people had successful MTBDR*plus* and FTMTBDR results, 90% of which were concordant (19 resistant, 70 susceptible) and 10 discordant [8
FT-MTBDR resistant and MTBDR*plus* susceptible, 2 FT-MTBDR susceptible and MTBDR*plus*resistance; SMOR supported the FT-MTBDR result in 90% (9/10) people]. The sensitivity of FTMTBDR for isoniazid resistance was better than MTBDR*plus* [53% (20/38) vs 71% (27/38);
p=0.0983], whereas specificity remained similar [98% (60/61) vs 100% (60/60); p=0.3193]
(Supplementary Material Table 2).

#### 219 Discussion

220 To our knowledge, this study is the first to describe rifampicin susceptibility discordance between the 221 WHO-recommended rapid molecular tests Ultra and MTBDRplus. Our key findings are: 1) Most 222 discordance (79%) was from MTBDRplus not detecting rifampicin-resistance and 2) 69% of these 223 MTBDR*plus*-susceptible were detected as FT-MTBDR resistant, indicating FT-MTBDR has higher 224 sensitivity than MTBDRplus. However, 3) a substantial proportion with sequencing-detected 225 resistance (31%; all of which were heteroresistant) were missed by FT-MTBDR and, in people with 226 heteroresistance, multiple resistant strains were often present. Furthermore, 4) although the Ultra 227 heteroresistance probe pattern was associated with heteroresistance, this pattern had suboptimal 228 sensitivity and specificity for heteroresistance and was itself associated with Ultra false-resistant calls 229 (as was lower mycobacterial load). Lastly, 5) more than half of the individuals were rifampicin mono-230 resistant, supporting the need for isoniazid DST. These data have implications for laboratory DST 231 algorithms, especially resolution of discordant results by different molecular methods.

232 Most rifampicin resistance discordance arose from MTBDRplus not detecting RAVs, rather than Ultra 233 falsely detecting RAVs. This might be because MTBDRplus interpretation is subjective even with the 234 semi-automated GenoScan and requires human reporting. In contrast, FT-MTBDR reporting is fully 235 automated. While FT-MTBDR identified most resistance missed by MTBDRplus, approximately half 236 of the isolates FT-MTBDR detected as rifampicin-susceptible had sequencing-detected resistance. 237 This contrasts with other studies that have reported FT-MTBDR sensitivities approaching 100%,<sup>2</sup> 238 however, these were done in Ultra rifampicin-resistant people (without specifically selecting the 239 discordant MTBDRplus-susceptible subset).

240 Heteroresistance, which we show to be a cause of Ultra-MTBDRplus discordance was, about a third 241 of the time, missed by FT-MTBDR. However, as these people were MTBDRplus-susceptible, FT-242 MTBDR is still substantially better at detecting resistance than the previous generation technology. 243 Interestingly, within people with sequencing-detected heteroresistance, there was seldom one resistant 244 strain implicated, which is unexpected given that these are not samples taken from people on 245 treatment and sequencing was done after culture, which can result in loss of minority variants.<sup>8</sup> 246 Possible causes of this diversity include multiple exposures to rifampicin-resistant TB or substantial 247 intra-host evolution.

248 Certain probe patterns reported by Ultra have been proposed to be useful for diagnosing 249 heteroresistance,<sup>10</sup> which may be clinically useful if first-line drugs could be included in the regimen 250 to rapidly reduce bacterial load of the drug-susceptible subpopulation.<sup>19, 20</sup> However, in our study, 251 although this Ultra probe pattern was indeed associated with heteroresistance, it did not translate into 252 high sensitivity and specificity for heteroresistance. While FT-MTBDR does not currently offer a 253 heteroresistance readout, this feature could be incorporated into its software to potentially inform

treatment. Lastly, this Ultra hetereoresistance pattern (as well as that from FT-MTBDR) was also associated with Ultra false-resistance calls, as was the Ultra "very low" semi-quantitation category. This category is a recognized risk factor for Xpert false-resistance,<sup>6</sup> for which repeat testing is recommended. Our data therefore suggests that samples with an Ultra heteroresistance pattern and or "very low" bacterial load should be considered at increased risk for false-resistance. The utility of repeat testing in such samples warrants further evaluation.

Our findings emphasize the importance of not assuming rifampicin-resistance equates to isoniazid resistance, particularly in cases of discordant Ultra-MTBDR*plus* results. Previous studies have demonstrated 19%<sup>21</sup> and 21%<sup>22</sup> of Xpert rifampicin-resistant cases are isoniazid-susceptible by MTBDR*plus*. Our data therefore support the scale-up of upfront routine isoniazid DST to avoid the inappropriate exclusion of isoniazid from regimens.

265 Our study has strengths and limitations. Ultra was done on specimens, while MTBDRplus, FT-266 MTBDR and SMOR were done on isolates. While this may be representative of some programmatic 267 algorithms, changes in subpopulation structures due to culture bias could create discordance. 268 Furthermore, phenotypic susceptibility testing was not possible as isolates were not stored to preserve 269 viability. However, SMOR has high sensitivity and specificity for phenotypic (and sub-phenotypic) resistance.<sup>7</sup> Another consideration is that our study was designed to investigate Ultra-resistant, 270 271 MTBDRplus-susceptible discordance, rather than to assess Ultra rifampicin resistant calls in all comers (which others have done for Ultra's predecessor Xpert).<sup>6</sup> In other words, our findings should 272 273 be interpreted within the context of samples pre-selected because they were Ultra-MTBDRplus 274 discordant (such discordant samples are likely not representative of typical RAVs in our setting).

In conclusion, patients with Ultra rifampicin-resistant TB that were susceptible by MTBDR*plus* are predominantly truly rifampicin resistant unless Ultra produced a heteroresistant probe pattern or "very low" semi-quantitation category (both associated with false Ultra rifampicin results). Isoniazid, for which susceptibility testing should be done, likely remains useful in people with this Ultra-MTBDR*plus* discordance.

## 280 Author Contributions

All named authors were involved in conceptualization and design of the study. Y.G., A.A., G.B. and E.A. assisted with specimen collection and specimen processing. F.N. M.F. and D.E. performed SMOR testing. Y.G., G.T., E.A., R.V., M.F., F.N. and D.E. performed formal analysis, methodology and writing original draft. All authors had full access to the de-identified data. All authors reviewed and edited the manuscript and had final responsibility for the decision to submit for publication.

# 286 Data Sharing

287 Study data can be accessed on request from the corresponding author without restriction.

## 288 Declaration of interests

G.T. acknowledges funding from the EDCTP2 programme supported by the European Union
(RIA2018D-2509, PreFIT; RIA2018D-2493, SeroSelectTB; RIA2020I-3305, CAGE-TB) and the
National Institutes of Health (D43TW010350; U01AI152087; U54EB027049; R01AI136894). Y.G.
and R.W. acknowledges funding from the South African Medical Research Council. D.E.
acknowledges funding from the National Institutes of Health (R01AI131939).

# 294 Acknowledgments


295 The authors thank the National Health Laboratory (NHLS) as a source of data and the staff of 296 Greenpoint Tuberculosis Laboratory, NHLS, Cape Town, South Africa for assisting with collecting 297 samples. We would like to thank the staff from Clinical Mycobacteriology and Epidemiology 298 (CLIME) Group, Division of Molecular and Human Genetics, Stellenbosch University for their 299 support in performing FT-MTBDR. Hain-Bruker Lifesciences donated FT-MTBDR consumables and 300 loaned the GenoXtract fleXT and FluoroCyclerXT-96 equipment but had no other role in the study. 301 T-Gen provided instrumentation and reagents needed for SMOR processing.

## 302 Figure legends

303 Figure 1. Study profile. We quantified discordant rifampicin susceptibility results (Ultra-resistant, 304 MTBDRplus-susceptible) done at TB diagnosis on respiratory specimens over an 18-month period. 305 The distribution of HR is shown, and most isolates that were confirmed by sequencing have RAVs 306 missed by MTBDR*plus* but often detected by FT-MTBDR. Abbreviations: FT-MTBDR, FluoroType 307 MTBDR: MicroHR, microheteroresistance; MacroHR, macroheteroresistance: MTBC. 308 Mycobacterium tuberculosis complex; SMOR, single molecule-overlapping repeats; RAV, resistance-309 associated variant; TB, tuberculosis; Ultra, Xpert MTB/RIF Ultra.

- **310** Figure 2. Examples of an Ultra report generated by the GeneXpert software showing melt peak
- 311 temperatures for each amplicon. (A) is a commonly seen rifampicin-resistant specimen with a
- 312 variant in the rpoB2 region. There is no indication of HR because, for rpoB2, "melt" has no value but
- 313 "mut melt" does (black arrows). In contrast, (**B**) has, for rpoB1, both "melt" and "mut melt" values,
- 314 suggesting HR. Abbreviations: °C; degree Celsius; HR, heteroresistance; melt, wild type melt peak
- temperature; mut melt, mutant melt peak teak temperature; Ultra, Xpert MTB/RIF Ultra.

# 316 Figure 1. Study Profile



317

# 319 Figure 2.

Α	Analyte Name	Melting Peak Temperature (°C)	В	Analyte Name	Melting Peak Temperature (°C)
	rpoB1 melt	69.6		rpoB1 melt	69.0
	rpoB2 melt			rpoB2 melt	72.9
	rpoB3 melt	75.6		rpoB3 melt	75.8
	rpoB4 melt	67.3		rpoB4 melt	67.1
	rpoB1 Mut melt			rpoB1 Mut melt	64.4
	rpoB2 Mut melt <b>———</b>	68.7		rpoB2 Mut melt	
	rpoB3 Mut melt			rpoB3 Mut melt	
	rpoB4 Mut melt A			rpoB4 Mut melt A	
	rpoB4 Mut melt B			rpoB4 Mut melt B	

321

320

- 323 Table 1. Ultra parameters among true- and false-Ultra rifampicin-resistant results, in people who were
- 324 MTBDR*plus*-susceptible, using SMOR on DNA from isolates as a reference standard. Ultra
- heteroresistance calls and lower detected bacillary load are more frequent among false-resistance
- 326 results. Data are median (IQR) or % (n/N).

	True rifampicin-resistant (n=77)	False rifampicin-resistant (n=20)			
C <sub>Tmin</sub>	19 (18-25)	29 (27-31); <b>p=0.0001</b>			
Semi-quantitation category					
High	40 (31/77)	5 (1/20); p=0.0028			
Medium	31 (24/77)	15 (3/20); p=0.1506			
Low	12 (9/77)	25 (5/20); p=0.1312			
Very low	17 (13/77)	55 (11/20); <b>p=0.0004</b>			
Specific probes with mutation label					
rpoB1 Mut	47 (32/68)	41 (7/17); p=0.6633			
rpoB2 Mut	13 (9/68)	18 (3/17); p=0.6403			
rpoB3 Mut	4 (3/68)	12 (2/17); p=0.2491			
rpoB4 Mut A	13 (9/68)	12 (2/17); p=0.8716			
rpoB4 Mut B	29 (2/68)	6 (1/17); p=0.5567			
More than one MUT probe	19 (13/68)	12 (2/17); p=0.4769			
Ultra heteroresistance pattern					
Heteroresistance pattern	32 (25/77)	60 (12/20); <b>p=0.0239</b>			
-	. ,				

- 327 Abbreviations: CTmin, cycle threshold minimum; HR, heteroresistance; MUT, mutation; Ultra, Xpert
- 328 MTB/RIF Ultra. P-values are for within row comparisons across columns.

# 330 **References**

Shin SS, Modongo C, Baik Y, Allender C, Lemmer D, Colman RE, et al. Mixed Mycobacterium
 tuberculosis-Strain Infections Are Associated With Poor Treatment Outcomes Among Patients With
 Newly Diagnosed Tuberculosis, Independent of Pretreatment Heteroresistance. J Infect Dis.
 2018;218(12):1974-82.

Dippenaar A, Derendinger B, Dolby T, Beylis N, van Helden PD, Theron G, et al. Diagnostic
 accuracy of the FluoroType MTB and MTBDR VER 2.0 assays for the centralized high-throughput
 detection of Mycobacterium tuberculosis complex DNA and isoniazid and rifampicin resistance. Clin
 Microbiol Infect. 2021;27(9):1351 e1- e4.

339 3. de Vos M, Derendinger B, Dolby T, Simpson J, van Helden PD, Rice JE, et al. Diagnostic
340 Accuracy and Utility of FluoroType MTBDR, a New Molecular Assay for Multidrug-Resistant
341 Tuberculosis. J Clin Microbiol. 2018;56(9).

Ghebrekristos Y. Characterization of Mycobacterium tuberculosis isolates with discordant
 rifampicin susceptibility test results: University of Cape Town; 2018.

Beylis N, Ghebrekristos Y, Nicol M. Management of false-positive rifampicin resistant Xpert
 MTB/RIF. Lancet Microbe. 2020;1(6):e238.

346 6. Ngabonziza JCS, Decroo T, Migambi P, Habimana YM, Van Deun A, Meehan CJ, et al.
347 Prevalence and drivers of false-positive rifampicin-resistant Xpert MTB/RIF results: a prospective
348 observational study in Rwanda. Lancet Microbe. 2020;1(2):e74-e83.

349 7. Metcalfe JZ, Streicher E, Theron G, Colman RE, Allender C, Lemmer D, et al. Cryptic
 350 Microheteroresistance Explains Mycobacterium tuberculosis Phenotypic Resistance. Am J Respir Crit
 351 Care Med. 2017;196(9):1191-201.

Metcalfe JZ, Streicher E, Theron G, Colman RE, Penaloza R, Allender C, et al. Mycobacterium
 tuberculosis Subculture Results in Loss of Potentially Clinically Relevant Heteroresistance.
 Antimicrob Agents Chemother. 2017;61(11).

Engelthaler DM, Streicher EM, Kelley EJ, Allender CJ, Wiggins K, Jimenez D, et al. Minority
 Mycobacterium tuberculosis Genotypic Populations as an Indicator of Subsequent Phenotypic
 Resistance. Am J Respir Cell Mol Biol. 2019;61(6):789-91.

35810.Chakravorty S, Simmons AM, Rowneki M, Parmar H, Cao Y, Ryan J, et al. The New Xpert359MTB/RIF Ultra: Improving Detection of Mycobacterium tuberculosis and Resistance to Rifampin in an360Assay Suitable for Point-of-Care Testing. mBio. 2017;8(4).

361 11. Xpert<sup>®</sup> MTB/RIF Ultra (package insert) [Internet]. 2019 [cited 28 February 2023]. Available
 362 from: https://www.biovendor.sk/download/30352/Manual\_xpert\_mtb-rif\_ultra.pdf.

363 12. GenoType MTBDRplus VER 2.0 [Internet]. 2015 [cited February 2023]. Available from:
 364 https://www.hain-

365 <u>lifescience.de/include\_datei/kundenmodule/packungsbeilage/download.php?id=936.</u>

366 13. GXT96 X2 Extraction Kit Version 1 (Package insert) [Internet]. 2022 [cited 2024-07-25].
 367 Available from: https://www.hain-lifescience.de/en/instructions-for-use.html.

Kocagoz T, Yilmaz E, Ozkara S, Kocagoz S, Hayran M, Sachedeva M, et al. Detection of
Mycobacterium tuberculosis in sputum samples by polymerase chain reaction using a simplified
procedure. J Clin Microbiol. 1993;31(6):1435-8.

15. Colman RE, Schupp JM, Hicks ND, Smith DE, Buchhagen JL, Valafar F, et al. Detection of LowLevel Mixed-Population Drug Resistance in Mycobacterium tuberculosis Using High Fidelity Amplicon
Sequencing. PLoS One. 2015;10(5):e0126626.

16. Colman RE, Anderson J, Lemmer D, Lehmkuhl E, Georghiou SB, Heaton H, et al. Rapid Drug
Susceptibility Testing of Drug-Resistant Mycobacterium tuberculosis Isolates Directly from Clinical
Samples by Use of Amplicon Sequencing: a Proof-of-Concept Study. J Clin Microbiol.
2016;54(8):2058-67.

378 17. Derendinger B, Dippenaar A, de Vos M, Huo S, Alberts R, Tadokera R, et al. Bedaquiline
379 resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective
380 longitudinal cohort study. Lancet Microbe. 2023;4(12):e972-e82.

18. FluoroType MTBDR VER 2.0 (Package insert) [Internet]. Hain Lifescience (Brucker). 2024
 [cited 2024-07-25]. Available from: <u>https://www.hain-lifescience.de/en/instructions-for-use.html</u>.

383 19. Department of Health (DOH) RoSA. Management of rifampicin resistant tuberculosis: A
 384 Clinical reference guide. South Africa; 2020.

Health WCDo. Clinical Guidelines & Standard Operating Procedure for the Implementation of
 the Short & Long DR-TB regimens for Adults, Adolescents and Children. South Africa; 2018
 September 2018.

Bisimwa BC, Nachega JB, Warren RM, Theron G, Metcalfe JZ, Shah M, et al. Xpert
Mycobacterium tuberculosis/Rifampicin-Detected Rifampicin Resistance is a Suboptimal Surrogate
for Multidrug-resistant Tuberculosis in Eastern Democratic Republic of the Congo: Diagnostic and
Clinical Implications. Clin Infect Dis. 2021;73(2):e362-e70.

Pillay S, de Vos M, Derendinger B, Streicher EM, Dolby T, Scott LA, et al. Non-actionable
Results, Accuracy, and Effect of First- and Second-line Line Probe Assays for Diagnosing DrugResistant Tuberculosis, Including on Smear-Negative Specimens, in a High-Volume Laboratory. Clin
Infect Dis. 2023;76(3):e920-e9.